Blockade of IL-13 signaling improves skin barrier function and biology in patients with moderate to severe atopic dermatitis.

Nicole SanderDora StölzlMelina FonfaraJan HartmannInken HarderIna SuhrkampIvone JakašaEllen van den BogaardIvonne van Vlijmen-WillemsSilke SzymczakElke RodriguezSascha GerdesStephan Weidinger

Published in: The British journal of dermatology (2024)

Tralokinumab treatment improves skin physiology, epidermal pathology, and dysbiosis, further highlighting the pleiotropic role of IL-13 in AD pathogenesis.

Keyphrases

wound healing
atopic dermatitis
soft tissue
high intensity
early onset